Potentiation of nitric oxide-induced apoptosis of MDA-MB-468 cells by farnesyltransferase inhibitor: Implications in breast cancer

Cancer Research

Volumn 61, Issue 12, 2001, Pages 4701-4706

  Pervin, Shehla ^a   Singh, Rajan ^a   Gau, Chia Ling ^a   Edamatsu, Hironori ^a   Tamanoi, Fuyuhiko ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 9; CYTOCHROME C; DETA NONOATE; NITRIC OXIDE; NITRIC OXIDE DONOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; SCH 56582; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG HALF LIFE; DRUG MECHANISM; HUMAN; HUMAN CELL; MACROPHAGE ACTIVATION; PRIORITY JOURNAL;

ALKYL AND ARYL TRANSFERASES; APOPTOSIS; BREAST NEOPLASMS; DRUG SYNERGISM; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; HUMANS; NITRIC OXIDE; NITRIC OXIDE DONORS; NITROSO COMPOUNDS; TUMOR CELLS, CULTURED;

EID: 0035874941     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Nitric oxide: A physiologic messenger molecule
2. Nitric oxide: Physiology, pathophysiology, and pharmacology
3. Cell signaling by nitric oxide
4. Role of nitric oxide in mediation of macrophage cytotoxicity and apoptosis
5. Inducible NO synthase. Role in cellular signaling
6. Apoptotic death of human leukemic cells induced by vascular cells expressing nitric oxide synthase in response to γ-interferon and tumor necrosis factor-α
7. Nitric-oxide-induced apoptosis in human leukemic lines requires mitochondrial lipid degradation and cytochrome c release
8. Nitric oxide induces apoptosis in mouse thymocytes
9. Nitric oxide and its role in apoptosis
10. Nitric oxide as a bifunctional regulator of apoptosis
11. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics
12. Prenylation of RAS and inhibitors of prenyltransferases
13. Farnesyltransferase inhibitors: Anti-ras drugs for cancer treatment?
14. Protein prenylation: Molecular mechanisms and functional consequences
15. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development
16. A Phase I trial of the farnesyltransferase inhibitor SCH66336: Evidence for biological and clinical activity
17. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice
18. Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines
19. Farnesyltransferase inhibitors cause enhanced mitotic sensitivity to taxol and epophilones
20. Farnesyltransferase inhibitors induce dramatic morphological changes of KNRK cells that are blocked by microtubule interfering agents
21. Antitumor activity of SCH66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and Wap-ras transgenic mice
22. Interaction of the farnesyl protein transferase inhibitor R 11577 with cytotoxic chemotherapeutics in vitro and in vivo
23. Activation of the PI3 K-AKT pathway masks the proapoptotic effects of farnesyltransferase inhibitors
24. Mitochondrion as a novel target of anticancer chemotherapy
25. Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells
26. Nitric oxide-mediated apoptosis in human breast cancer cells requires changes in mitochondrial functions and is independent of CD95 (APO-1/Fas)
27. Mechanisms of nitric oxide-dependent apoptosis: Involvement of mitochondrial mediators
28. Nitric Oxide induced cytostasis and cell cycle arrest of a human breast cancer cell line (MDA-MB-231): Potential role of cyclin D1
29. Nitrosative capacity of macrophages is dependent on nitric-oxide synthase induction signals
30. Novel tricyclic inhibitors of farnesyl protein transferase. Biochemical characterization and inhibition of Ras modification in transfected Cos cells
31. Blockage of chemotactic peptide-induced stimulation of neutrophils by wortmanin as a result of selective inhibition of phosphatidylinositol 3-kinase
32. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cadk2, and cadk5
33. Intracellular K+ suppresses the activation of apoptosis in lymphocytes
34. Apoptosis in the absence of cytochrome c accumulation in the cytosol
35. Morphological expression of cell transformation induced by c-Ha-ras oncogene in human breast epithelial cells
36. Additive effects of c-erbB-2, c-Ha-ras, and transforming growth factor-α genes on in vitro transformation of human mammary epithelial cells
37. Antitumor activity of a novel glyco-nitric oxide conjugate in ovarian carcinoma
38. Induction of inducible nitric oxide synthase is an essential part of tumor necrosis factor-α-induced apoptosis in MCF-7 and other epithelial tumor cells
39. Endogenous endothelial cell nitric-oxide synthase modulates apoptosis in cultured breast cancer cells and is transcriptionally regulated by p53
40. Functional implications of nitric oxide produced by mitochondria in mitochondrial metabolism
41. Mitochondrial nitric-oxide synthase stimulation causes cytochrome c release from isolated mitochondria. Evidence for intramitochondrial peroxynitrite formation